Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”

Marcus S. Shaker; Elizabeth Phillips; Kimberly G. Blumenthal; Elissa M. Abrams; Aleena Banerji; John Oppenheimer; Timothy K. Vander Leek; Douglas P. Mack; Paige G. Wickner; Alexander G. Singer; David A. Khan; Matthew Greenhawt

doi:10.1016/j.jaip.2021.03.016

Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”

Marcus S. Shaker, Elizabeth Phillips, Kimberly G. Blumenthal, Elissa M. Abrams, Aleena Banerji, John Oppenheimer, Timothy K. Vander Leek, Douglas P. Mack, Paige G. Wickner, Alexander G. Singer, David A. Khan, Matthew Greenhawt

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2537-2539
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	9
Issue number	6
DOIs	https://doi.org/10.1016/j.jaip.2021.03.016
State	Published - Jun 2021

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2021.03.016

Cite this

Shaker, M. S., Phillips, E., Blumenthal, K. G., Abrams, E. M., Banerji, A., Oppenheimer, J., Vander Leek, T. K., Mack, D. P., Wickner, P. G., Singer, A. G., Khan, D. A., & Greenhawt, M. (2021). Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”. Journal of Allergy and Clinical Immunology: In Practice, 9(6), 2537-2539. https://doi.org/10.1016/j.jaip.2021.03.016

Shaker, MS, Phillips, E, Blumenthal, KG, Abrams, EM, Banerji, A, Oppenheimer, J, Vander Leek, TK, Mack, DP, Wickner, PG, Singer, AG, Khan, DA & Greenhawt, M 2021, 'Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”', Journal of Allergy and Clinical Immunology: In Practice, vol. 9, no. 6, pp. 2537-2539. https://doi.org/10.1016/j.jaip.2021.03.016

@article{f27cfe576cc844bf980b7ee4ac72e87c,

title = "Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”",

author = "Shaker, {Marcus S.} and Elizabeth Phillips and Blumenthal, {Kimberly G.} and Abrams, {Elissa M.} and Aleena Banerji and John Oppenheimer and {Vander Leek}, {Timothy K.} and Mack, {Douglas P.} and Wickner, {Paige G.} and Singer, {Alexander G.} and Khan, {David A.} and Matthew Greenhawt",

note = "Funding Information: Conflict of interest: M. S. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; has a family member who is CEO of Altrix Medical; and serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. E. Phillips reports grants from the National Institutes of Health (grant nos. P50GM115305, R01HG010863, R01AI152183, R21AI139021, and U01AI154659) and from the National Health and Medical Research Council of Australia; receives Royalties from UpToDate and consulting fees from Janssen Vertex, Regeneron, and Biocryst; is codirector of IIID Pty Ltd, which holds a patent for HLA-B∗57:01 testing for abacavir hypersensitivity; and has a patent pending for Detection of Human Leukocyte Antigen-A∗32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. E. M. Abrams is on the Steering Committee of Food Allergy Canada's National Food Allergy Action Plan; is a collaborator with the Institute for Health metrics and Evaluation; and has received moderator/speaker fees from AstraZeneca (AZ), GlaxoSmithKline (GSK), and Sanofi. J. Oppenheimer declares the following: Research/Adjudication: AZ, GSK, Sanofi, and Novartis; Consultant: GSK, AZ, and Sanofi; Associate Editor: Annals of Allergy, Asthma, and Immunology, AllergyWatch; Section Editor: Current Opinion of Allergy; Royalties: UptoDate; and Board Liaison American Board of Internal Medicine for American Board of Allergy and Immunology. T. L. V. Leek has served on advisory boards and received honoraria from Aralez, Bausch Health, and Pfizer. D. P. Mack is a member of the Board of Directors for the Canadian Society of Allergy and Clinical Immunology; serves on the Editorial Board of the Journal of Food Allergy; has provided consultation and speaker services for Pfizer, Aimmune, Merck, Covis, and Pediapharm and has been part of an advisory board for Pfizer and Bausch Health. M. Greenhawt has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, Aravax, and Monsanto; is a member of the Scientific Advisory Council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma, and Immunology, and the Eurpoean Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflict of interest: M. S. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; has a family member who is CEO of Altrix Medical; and serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. E. Phillips reports grants from the National Institutes of Health (grant nos. P50GM115305 , R01HG010863 , R01AI152183 , R21AI139021 , and U01AI154659 ) and from the National Health and Medical Research Council of Australia; receives Royalties from UpToDate and consulting fees from Janssen Vertex, Regeneron, and Biocryst; is codirector of IIID Pty Ltd, which holds a patent for HLA-B∗57:01 testing for abacavir hypersensitivity; and has a patent pending for Detection of Human Leukocyte Antigen-A∗32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. E. M. Abrams is on the Steering Committee of Food Allergy Canada's National Food Allergy Action Plan; is a collaborator with the Institute for Health metrics and Evaluation; and has received moderator/speaker fees from AstraZeneca (AZ), GlaxoSmithKline (GSK), and Sanofi. J. Oppenheimer declares the following: Research/Adjudication: AZ, GSK, Sanofi, and Novartis; Consultant: GSK, AZ, and Sanofi; Associate Editor: Annals of Allergy, Asthma, and Immunology, AllergyWatch; Section Editor: Current Opinion of Allergy; Royalties: UptoDate; and Board Liaison American Board of Internal Medicine for American Board of Allergy and Immunology. T. L. V. Leek has served on advisory boards and received honoraria from Aralez, Bausch Health, and Pfizer. D. P. Mack is a member of the Board of Directors for the Canadian Society of Allergy and Clinical Immunology; serves on the Editorial Board of the Journal of Food Allergy; has provided consultation and speaker services for Pfizer, Aimmune, Merck, Covis, and Pediapharm and has been part of an advisory board for Pfizer and Bausch Health. M. Greenhawt has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, Aravax, and Monsanto; is a member of the Scientific Advisory Council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma, and Immunology, and the Eurpoean Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. The rest of the authors declare that they have no relevant conflicts of interest. ",

year = "2021",

month = jun,

doi = "10.1016/j.jaip.2021.03.016",

language = "English (US)",

volume = "9",

pages = "2537--2539",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”

AU - Shaker, Marcus S.

AU - Phillips, Elizabeth

AU - Blumenthal, Kimberly G.

AU - Abrams, Elissa M.

AU - Banerji, Aleena

AU - Oppenheimer, John

AU - Vander Leek, Timothy K.

AU - Mack, Douglas P.

AU - Wickner, Paige G.

AU - Singer, Alexander G.

AU - Khan, David A.

AU - Greenhawt, Matthew

N1 - Funding Information: Conflict of interest: M. S. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; has a family member who is CEO of Altrix Medical; and serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. E. Phillips reports grants from the National Institutes of Health (grant nos. P50GM115305, R01HG010863, R01AI152183, R21AI139021, and U01AI154659) and from the National Health and Medical Research Council of Australia; receives Royalties from UpToDate and consulting fees from Janssen Vertex, Regeneron, and Biocryst; is codirector of IIID Pty Ltd, which holds a patent for HLA-B∗57:01 testing for abacavir hypersensitivity; and has a patent pending for Detection of Human Leukocyte Antigen-A∗32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. E. M. Abrams is on the Steering Committee of Food Allergy Canada's National Food Allergy Action Plan; is a collaborator with the Institute for Health metrics and Evaluation; and has received moderator/speaker fees from AstraZeneca (AZ), GlaxoSmithKline (GSK), and Sanofi. J. Oppenheimer declares the following: Research/Adjudication: AZ, GSK, Sanofi, and Novartis; Consultant: GSK, AZ, and Sanofi; Associate Editor: Annals of Allergy, Asthma, and Immunology, AllergyWatch; Section Editor: Current Opinion of Allergy; Royalties: UptoDate; and Board Liaison American Board of Internal Medicine for American Board of Allergy and Immunology. T. L. V. Leek has served on advisory boards and received honoraria from Aralez, Bausch Health, and Pfizer. D. P. Mack is a member of the Board of Directors for the Canadian Society of Allergy and Clinical Immunology; serves on the Editorial Board of the Journal of Food Allergy; has provided consultation and speaker services for Pfizer, Aimmune, Merck, Covis, and Pediapharm and has been part of an advisory board for Pfizer and Bausch Health. M. Greenhawt has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, Aravax, and Monsanto; is a member of the Scientific Advisory Council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma, and Immunology, and the Eurpoean Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflict of interest: M. S. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; has a family member who is CEO of Altrix Medical; and serves on the Editorial Board of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. E. Phillips reports grants from the National Institutes of Health (grant nos. P50GM115305 , R01HG010863 , R01AI152183 , R21AI139021 , and U01AI154659 ) and from the National Health and Medical Research Council of Australia; receives Royalties from UpToDate and consulting fees from Janssen Vertex, Regeneron, and Biocryst; is codirector of IIID Pty Ltd, which holds a patent for HLA-B∗57:01 testing for abacavir hypersensitivity; and has a patent pending for Detection of Human Leukocyte Antigen-A∗32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. E. M. Abrams is on the Steering Committee of Food Allergy Canada's National Food Allergy Action Plan; is a collaborator with the Institute for Health metrics and Evaluation; and has received moderator/speaker fees from AstraZeneca (AZ), GlaxoSmithKline (GSK), and Sanofi. J. Oppenheimer declares the following: Research/Adjudication: AZ, GSK, Sanofi, and Novartis; Consultant: GSK, AZ, and Sanofi; Associate Editor: Annals of Allergy, Asthma, and Immunology, AllergyWatch; Section Editor: Current Opinion of Allergy; Royalties: UptoDate; and Board Liaison American Board of Internal Medicine for American Board of Allergy and Immunology. T. L. V. Leek has served on advisory boards and received honoraria from Aralez, Bausch Health, and Pfizer. D. P. Mack is a member of the Board of Directors for the Canadian Society of Allergy and Clinical Immunology; serves on the Editorial Board of the Journal of Food Allergy; has provided consultation and speaker services for Pfizer, Aimmune, Merck, Covis, and Pediapharm and has been part of an advisory board for Pfizer and Bausch Health. M. Greenhawt has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, Aravax, and Monsanto; is a member of the Scientific Advisory Council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune, DBV, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma, and Immunology, and the Eurpoean Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85107153479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107153479&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2021.03.016

DO - 10.1016/j.jaip.2021.03.016

M3 - Letter

C2 - 34112481

AN - SCOPUS:85107153479

SN - 2213-2198

VL - 9

SP - 2537

EP - 2539

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 6

ER -

Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this